In a randomized double-blind placebo-con trolled study in 30 patients with acute ischemic stroke, the effect of the adenosine uptake blocker propentofylline on regional brain glucose metabolism (rCMRg1u) was in vestigated using repeated positron emission tomography (PET) with 2-[18F]fluoro-2-deoxY-D-glucose (FDG). Treatment was initiated within 48 h after onset of symp toms. The clinical course was followed for 3 months. In the propentofylline group, after 14 days rCMRgiu was in creased in the infarct by 37.3% and was practically un changed in other brain regions, whereas in the control group glucose metabolism had decreased in all regions
Summary:
In a randomized double-blind placebo-con trolled study in 30 patients with acute ischemic stroke, the effect of the adenosine uptake blocker propentofylline on regional brain glucose metabolism (rCMRg1u) was in vestigated using repeated positron emission tomography (PET) with 2-[18F]fluoro-2-deoxY-D-glucose (FDG). Treatment was initiated within 48 h after onset of symp toms. The clinical course was followed for 3 months. In the propentofylline group, after 14 days rCMRgiu was in creased in the infarct by 37.3% and was practically un changed in other brain regions, whereas in the control group glucose metabolism had decreased in all regions Excessive accumulation of excitatory amino ac ids (EAAs) plays an important role within the cas cade of biochemical processes contributing to isch emic cell damage (reviews, Choi, 1990; Benveniste, 1991) . The toxicity of EAAs is modulated by a va riety of other substances (Shimada et aI., 1990; Mat sumoto et aI., 1992) . Some of these, e. g. , glycine (Globus et aI., 1991) and dopamine (Globus et aI. , 1988) seem to enhance excitotoxicity, whereas oth ers, like adenosine (Hagberg et aI., 1987 a) , ,),-amino butyric acid (GAB A) and taurine (Hagberg et aI., 1987b; Globus et aI., 1988) may act in an opposite direction. Because blocking of the various recep tors responsive to EAAs causes side effects limiting (1.4-13.4% ). These differences were significant between the two groups [Analysis of variance (ANOV A) p = 0.005]. Although there was a trend toward greater clinical improvement in the propentofylline-treated patients, this did not reach statistical significance. The results corre spond to experimental data showing that propentofylline improves energy metabolism in cerebral ischemia. A clin ical trial is needed to determine whether this new thera peutic principle can be successfully used in acute human stroke. Key Words: Glucose metabolism-Propento fylline-Stroke-Positron emission tomography. clinical application (for reviews, see Olney et aI., 1989; Meyer, 1989; Buchan, 1990; Meldrum, 1990; Choi, 1990; Allen and Iversen, 1990) , enhancing mechanisms inhibiting excitotoxicity might be an effective and applicable clinical strategy. Propent ofylline (HWA 285, Hoechst AG) increases GABA (Vukadinovic et aI., 1986) and adenosine levels (An dine et aI., 1990) in the brain, and reduces glutamate release under ischemic conditions (Andine et aI., 1990; Miyashita et aI., 1992) . A neuroprotective ef fect against ischemic brain damage in gerbils was demonstrated (DeLeo et aI., 1988) . Pilot clinical studies using propentofylline did not reveal any ma jor adverse drug effects.
METHODS

Patient selection
The study protocol had the approval of the Ethics Com mittee of the Medical Faculty. Patients of either sex who met the following criteria qualified for entry into the study: age 45 to 80 years, acute completed ischemic stroke, and completion of the clinical diagnosis within 48 h after onset of symptoms. The diagnosis was based on typical history confirmed by a complete neurologic workup including a computed tomography (CT) scan. Ex clusion criteria consisted in subarachnoid hemorrhage, intracerebral hematoma, recent myocardial or brain in farctioI)., persistent cardiac arrhythmia or circulatory in sufficiency, severe renal or hepatic failure, severe sys temic infection, nonstabilized diabetes mellitus, or coma. None of the patients was on aspirin or heparin treatment. Written informed consent to the study was obtained from the patient or from the next of kin. Clinical assessment on admission and after 2 weeks of treatment used the Mathew Score (Mathew et aI., 1972) ; patients with initial scores >65 were excluded. The Barthel Index (Mahoney and Barthel, 1965) was determined after periods of 14 days and 3 months. FDG PET was performed on the day of admission and repeated 14 days later.
Treatment regimen and drug administration
After clinical assessment and a first PET study, pa tients were randomly assigned to either control or pro pentofylline group and remained in the neurologic inten sive care unit for at least 1 week. A standard treatment including 6% hydroxyethylstarch (500 ml/day, i.v., for 14 days) and 10% glycerol solution, i.v., for 5 days was com mon to both groups. In addition, propentofylline patients received the drug as a continuous i. v. infusion of 1,200 mg within 24 hours for 7 days, whereas placebo patients were given carrier solution instead, provided in indistinguish able ampUles. Drug and placebo were packed in boxes identifiable only by the random number; all prepackaged study materials were supplied by Hoechst AG (Werk Kalle-Albert, Wiesbaden, Germany). During the whole treatment period, no serious drug-related side effects were observed.
FDG PET studies
rCMRgiu was studied using FDG PET (Reivich et aI., 1979 ) on a four-ring positron camera (Scanditronix PC384) (Eriksson et aI., 1982) , after intravenous injection of 185 MBq (5 mCi) FDG [synthesized according to the method of Ehrenkaufer et ai. (1984) ]. Scanning, image processing for providing comparable image data sets, and regional quantitation procedures have been described elsewhere in detail (Heiss et aI., 1984; Herholz et aI., 1985; Pawlik et aI., 1986; Wienhard et aI., 1985) . In the initial FDG PET studies, all patients exhibited a region with extremely low rCMRg1u, representing the infarct as outlined on (late) radiographic CT. Regions showing grad ually decreased metabolism surrounded the infarct proper, and subnormal rCMRgiu in the ipsilateral hemi sphere and in the contralateral cerebellum indicated func tional deactivation. For regional analysis in each individ ual, rCMRgiu values of the infarct, noninfarcted ipsilateral cerebral gray matter (cortex, basal ganglia, thalamus), and ipsilateral whole hemisphere metabolism ("affected side") as opposed to the values on the "unaffected side" were determined. These data of either group were then subjected to calculation of percent changes of rCMRgiu between the two measurements.
Statistical methods
Descriptive statistics are presented as mean ± SD (range) or median (range), depending on the type of data. For evidence of association in 2 x 2 tables (e.g., sex x treatment, side x treatment), Fisher's exact test was used. Comparison of the two treatment groups used ei-ther parametric one-way analysis of variance (ANOV A) or nonparametric tests (rank sum test) as indicated. Glu cose metabolism absolute values were subjected to loga rithmic transformation. Treatment effects on rCMR JllU were assessed using ANOV A in a repeated measures {le sign with treatment as between-subject variables interact ing with within-subject variables region (infarct, nonin farcted ipsilateral hemispheric gray matter, or "mirror" regions contralaterally) and side (ipsilateral or contralat eral side of infarction). Probability values p ,;:; 0.05 are reported to be significant. A commercially available soft ware package was used (SAS, SAS Institute, Cary, NC, U.S.A.).
RESULTS
Clinical course
Thirty consecutive patients who met the above mentioned criteria were randomly assigned to either group. Mean duration of time between onset of symptoms and start of treatment was 25.3 ± 11.0 h. Without any obvious relation to treatment, three patients with large brain infarcts died during the first week after stroke. One was in the propentofyl line group, two were controls. The remaining 27 patients completed the main phase of the study (2 weeks and second PET study), showing no adverse drug effects. During the clinical follow-up period of 3 months, another two placebo-treated and two pro pentofylline-treated patients died of cardiac causes (two placebo, one propentofylline) and second brain infarction (one). Table 1 summarizes clinical data. Groups were balanced with respect to any of the first assessment variables. The Barthel index, which was comparable in both groups at the end of the treatment period, showed a larger trend toward improvement in the propentofylline group; how ever, these differences did not reach statistical sig nificance.
Brain glucose metabolism
As demonstrated in Table 2 , the groups were quite similar with respect to their initial metabolic depression (initial whole brain CMR g 1u in controls: 28.5 ± 3. 11, propentofylline 27.8 ± 4.25). During the observation period, global metabolism de creased further in the control group (25.9 ± 3.27) and was practically unchanged in the treatment group (27.4 ± 5.67). Although in the control group rCMR g 1u decreased in all regions, in the propento fylline group it increased in the infarct and was practically not altered in noninfarcted regions. This effect was proven to be statistically significant by repeated measures ANOVA which demonstrated a treatment effect (p = 0.005) different in various re gions (interaction Treatment x Region, p = 0.02), but independent of the side (affected or unaffected hemisphere). According to post hoc interaction contrasts this effect was mainly due to an effect on infarct and periinfarct tissue.
DISCUSSION
Large-scale trials are needed to determine the clinical value of newly designed drugs which proved to be effective in experimental models of ischemia. Such clinical trials require much effort and are ex tremely expensive. It seems advisable, therefore, that compounds should be carefully selected on the basis of whether they have been shown to influence measurable physiologic parameters important to the ischemic process. In several studies, PET measure ment of cerebral blood flow and metabolism has been used for the assessment of drug-related effects in acute human stroke (Hakim et aI., 1989; Heiss et aI., 1990) . The results of these studies were in line with those obtained from large clinical trials, indi cating that PET can be useful for assessing the ef fects of antiischemic drugs. The time window dur ing which reperfusion could reverse the ischemic process is very short, but some biochemical sequel ae of ischemia have been shown to continue even after perfusion is partially reinstituted (Siesjo and Bengtsson, 1989) , and periinfarct viable tissue has been found up to 48 h after the ischemic attack (Hakim, 1989; Heiss et aI., 1990 Heiss et aI., , 1992 . In the vi cinity of an ischemic infarct-sometimes called the penumbra zone (Astrup et aI., 198 1)-most neurons are possibly morphologically intact, thus being sus ceptible to the effects of drugs. Propentofylline has been shown to increase cerebral blood flow (Hudlicka et aI., 198 1; Grome et aI., 1985) , protect against ischemic damage (DeLeo et aI., 1987 (DeLeo et aI., , 1988 even when given after the arterial occlusion, in crease adenosine and GABA concentrations, re duce Ca2+ and glutamate accumulation (Vukadi novic et aI., 1986; DeLeo et aI., 1987; Andine et aI., 1990; Miyashita et aI., 1992) , and suppress the de velopment of postischemic cerebral edema (Sasaki et aI., 1989) . As in experimental cerebral ischemia (Takano et aI., 1985) , in our study in acute human stroke patients, propentofylline significantly in creased glucose metabolism when compared with placebo. Significant metabolic improvement within the infarct and preservation of metabolism in the surrounding brain was achieved despite the fact that treatment was initiated several hours after onset of symptoms. In animal experiments, increased glu cose metabolism in ischemic areas up to 1 hour Treatment p = 0.005 p = 0.05 n.s. p = 0.01 p = 0.02 p = 0.01 n.s.
after vessel occlusion was associated with later ne crosis and is probably due to excitotoxic mecha nisms (Shiraishi et aI., 1989) , but these phenomena are supposed to play a role only very early in the course of the disease. Preservation of metabolism of functionally inactivated brain structures remote to the infarct area was related to a more favorable long-term prognosis (Kushner et aI. , 1987) . In our study, whole hemispheric glucose metabolism ipsi lateral to the infarction 14 days after stroke was significantly increased in the propentofylline group, whereas there was a further decline in controls. Pre vious studies using the Ca2+ channel blocker nimo dipine (Hakim et aI., 1989; Heiss et aI., 1990) showed an increase of brain energy metabolism which was paralleled by a significant clinical im provement. In contrast, in our trial of propentofyl line the pronounced effect on brain metabolism was only weakly associated with improvements in the clinical outcome. Propentofylline patients fared slightly better than controls 3 months after the at tack, but these differences were not statistically sig nificant, possibly due to large variability among the small groups. From our results, we conclude that propentofylline enhances postischemic brain en ergy metabolism, but a clinical trial is needed to evaluate whether this effect is of clinical impor tance.
